Free tool
FAERS Monitor: Imaavy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761430 or its brand name (Imaavy, Nipocalimab-Aahu). Reports on generic versions are filed under their own applications.
Reports
318
Serious
119
37% of reports
Hospitalization
67
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective30
- myasthenia gravis25
- headache20
- oedema peripheral20
- fatigue18
- dyspnoea16
- influenza14
- off label use14
- product dose omission issue13
- infusion related reaction11
- rash11
- therapeutic response decreased11
- herpes zoster10
- pneumonia10
- asthenia9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 88 |
| 2026 | 230 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,841 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myasthenia gravisSignal | 25 | 205.4 | 140.9 | 4,869 |
| therapeutic response decreasedSignal | 11 | 12.0 | 6.7 | 100 |
| herpes zosterSignal | 10 | 11.5 | 6.3 | 86 |
| infusion related reactionSignal | 11 | 11.0 | 6.1 | 90 |
| oedema peripheralSignal | 20 | 10.9 | 7.1 | 170 |
| influenzaSignal | 14 | 8.3 | 5.0 | 83 |
| product dose omission issueSignal | 13 | 2.9 | 1.7 | 15 |
| headacheSignal | 20 | 2.1 | 1.4 | 11 |
| pneumoniaSignal | 10 | 2.0 | 1.1 | 4 |
| dyspnoea | 16 | 1.9 | 1.2 | 6 |
| rash | 11 | 1.7 | 0.9 | 2 |
| asthenia | 9 | 1.6 | 0.8 | 1 |
| fatigue | 18 | 1.5 | 1.0 | 3 |
| drug ineffective | 30 | 1.5 | 1.1 | 5 |
| off label use | 14 | 1.1 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.